Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Riboflavin
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Epi-ON Corneal Crosslinking UVA Safety In Down Syndrome with Ectatic Corneal Diseases
Details : Vitamin B2 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Down Syndrome.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 21, 2025
Lead Product(s) : Riboflavin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Epi-ON Corneal Crosslinking 18-Min Vs 24-Min UVA Exposure Safety and Efficacy
Details : Riboflavin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Keratoconus.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 15, 2025
Lead Product(s) : Riboflavin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable